Buy Or Sell: Mylan Stock

The company is focusing on higher-margin generic launches and its innovative portfolio, including late-stage assets expected to complete enrollment in 2026. Market Cap: ~$17.25 billion as of April 2026.

Discounted Cash Flow (DCF) models suggest the stock is significantly undervalued, with some estimates placing "fair value" as high as $56.03 . mylan stock buy or sell

Analysts are concerned about a lack of a clear growth strategy following an EBITDA "trough" expected in 2025 due to manufacturing issues. The company is focusing on higher-margin generic launches

To evaluate whether to "buy or sell," you must look at performance and analyst sentiment as of April 2026. Viatris (VTRS) Analyst Ratings & Price Targets (April 2026) Analysts are concerned about a lack of a

Viatris is currently viewed as a value play or income stock rather than a high-growth candidate. Its low valuation and steady dividends may make it a "buy" for long-term holders, while short-term traders might "hold" or "sell" due to flat price targets and operational headwinds.

The company expects 2026 to be a "pivotal year" with 2% revenue growth and $650 million in planned cost savings.

Recent FDA warnings and import alerts regarding manufacturing facilities in India (Indore and Nashik) continue to impact EBITDA estimates.